ROS1 D2033N

CI-VAR-00000452Explore in graph →CIViC 1641

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
ROS1 D2033N	Crizotinib	Predictive	C	Supports Resistance	—	submitted	EID4770 In a metastatic lung adenocarcinoma patient with a CD74-ROS1 gene fusion (a known sensitizing alteration to crizotinib) and a D2033N mutation in the ROS1 portion of the CD74-ROS1 gene fusion, D2033N w… (full text at CIViC) PMID 26673800 · Drilon et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma1
ROS1 D2033N	Cabozantinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID7691 A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months led to response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 D2033N mutation. S… (full text at CIViC) PMID 26673800 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Lung Neoplasm1
ROS1 D2033N	Crizotinib	Predictive	C	Supports Resistance	3	submitted	EID7685 In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC) PMID 29333528 · Gainor et al., 2017 · Open in CIViC	civic